- Home
- IROH vs CLRB Comparison
IROH vs CLRB Comparison
Compare IROH & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROH
- CLRB
- Stock Information
- Founded
- IROH 2021
- CLRB 2002
- Country
- IROH United States
- CLRB United States
- Employees
- IROH N/A
- CLRB N/A
- Industry
- IROH
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- IROH
- CLRB Health Care
- Exchange
- IROH Nasdaq
- CLRB Nasdaq
- Market Cap
- IROH 90.7M
- CLRB 76.0M
- IPO Year
- IROH 2023
- CLRB N/A
- Fundamental
- Price
- IROH $10.28
- CLRB $2.04
- Analyst Decision
- IROH
- CLRB Strong Buy
- Analyst Count
- IROH 0
- CLRB 2
- Target Price
- IROH N/A
- CLRB $21.00
- AVG Volume (30 Days)
- IROH 7.5K
- CLRB 237.5K
- Earning Date
- IROH 01-01-0001
- CLRB 11-18-2024
- Dividend Yield
- IROH N/A
- CLRB N/A
- EPS Growth
- IROH N/A
- CLRB N/A
- EPS
- IROH 0.72
- CLRB N/A
- Revenue
- IROH N/A
- CLRB N/A
- Revenue This Year
- IROH N/A
- CLRB N/A
- Revenue Next Year
- IROH N/A
- CLRB N/A
- P/E Ratio
- IROH $14.30
- CLRB N/A
- Revenue Growth
- IROH N/A
- CLRB N/A
- 52 Week Low
- IROH $9.97
- CLRB $1.82
- 52 Week High
- IROH $11.11
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- IROH N/A
- CLRB 50.95
- Support Level
- IROH N/A
- CLRB $2.06
- Resistance Level
- IROH N/A
- CLRB $2.18
- Average True Range (ATR)
- IROH 0.00
- CLRB 0.08
- MACD
- IROH 0.00
- CLRB 0.01
- Stochastic Oscillator
- IROH 0.00
- CLRB 52.17
About IROH Iron Horse Acquisitions Corp. Common Stock
Iron Horse Acquisitions Corp is a blank check company.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.